Nucleate Singapore Pulse

Dr. Goh Wei Jiang is the Co-founder and CEO of CraftHealth, a pioneering Singapore-based startup revolutionizing personalized medicine through 3D printing. With a background in pharmacy and a PhD-MBA from NUS, Dr. Goh brings both scientific expertise and commercial insight to the forefront of MedTech innovation. Drawing on his clinical experience and translational research, he co-founded CraftHealth to solve a real-world challenge: simplifying polypharmacy and improving drug compliance through customizable, on-demand medications.In this episode, Dr. Goh Wei Jiang shares his journey from hospital pharmacist to a Healthtech founder. Motivated by the challenge of polypharmacy and the pill burden faced by patients, Dr. Goh and his co-founder developed a 3D printing platform that enables personalized medicine—combining multiple drugs into a single, tailored pill with customized release profiles.He walks us through the early ideation phase, shaped by his experiences in Stanford Biodesign, GRIP, Lean Launchpad, and other innovation ecosystems, and how they tested their first 3D printed pill using a small grant. Dr. Goh explains how CraftHealth's proprietary platform integrates hardware, software, and material science to create a modular, scalable approach to medication production.Dr. Goh also explores real-world applications: from improving precision dosing in pediatric or renal patients to enabling compounding pharmacies and supplement companies to rapidly prototype and personalize products. He discusses regulatory challenges, automation, hospital partnerships, and long-term visions for decentralised drug manufacturing. Finally, he shares his reflections on entrepreneurship, emphasising the importance of customer validation and building what people are willing to pay for.Host: Dillon ChewEditors: Hana Maldivita Tambrin, Aakash S/O Naresh Kumar, Dillon ChewChapters:01:15 – Dr. Goh’s Background & Identifying the Problem of Polypharmacy08:50 – CraftHealth’s 3D Printing Platform (Hardware, Software, Materials, Data)13:15 – Use Cases 15:15 – Addressing Challenges, Regulatory & Commercial Fit24:00 – Expansion and growth strategies34:00 – Vision for Decentralized Drug Manufacturing and Closing

Dr. Abbas Sahili is the CTO of Singzyme, a biotechnology company pioneering next-generation bioconjugation technologies. With a strong background in biochemistry and structural biology, Abbas brings deep scientific expertise and entrepreneurial vision to the field of precision medicine. His transition from academia to biotech leadership is marked by a commitment to developing antibody-drug conjugates (ADCs) that are more efficient, effective, and accessible. Under his leadership, Singzyme has developed a proprietary platform leveraging Peptide Asparaginyl Ligase (PAL) technology, setting a new standard in ADC manufacturing and performance.In this episode, Dr. Abbas Sahili walks us through his unique journey from academic research in structural biology to founding Singzyme, a cutting-edge biotech startup. He shares the motivations that led him to pivot from lab-based research to real-world therapeutic development and the founding story of Singzyme.Dr. Sahili breaks down complex concepts like antibody-drug conjugates and bioconjugation in a way that’s easy to understand. He discusses Singzyme’s PAL technology, a novel enzymatic platform that offers significant advantages over traditional methods, particularly in oncology and diagnostic imaging. He explains how PAL improves efficiency and precision in linking payloads to antibodies, unlocking new possibilities in targeted therapies and radiodiagnostics.He also sheds light on the operational and strategic challenges faced by a young biotech company and outlines how Singzyme is overcoming them through innovation, industry partnerships, and a strong vision. Looking ahead, Abbas discusses the potential for expanding beyond cancer into other areas like autoimmune and infectious diseases, and the roadmap for product development and partnerships.Host: Dillon Chew Editors: Hana Maldivita Tambrin, Aakash S/O Naresh Kumar, Dillon Chew01:10 Dr. Sahili’s Background and Academic Journey04:30 Transition from Research to Entrepreneurship07:00 Founding Story of Singzyme10:15 Overview of Antibody-Drug Conjugates (ADCs)13:45 What Makes PAL Technology Unique17:30 Challenges in Traditional Bioconjugation Methods21:00 Application of PAL in Radiodiagnostics24:45 Singzyme’s Milestones Since 202128:30 Partnerships and Industry Collaboration32:15 Future Expansion Beyond Oncology36:00 Roadmap for the Next 3–5 Years40:20 Advice for Young Scientists and Aspiring Founders

Dr. Hoa Giang is the Co-founder and Data Science Lead of Gene Solutions. His background boasts a broad range of experience in the global therapeutics industry. His technical background includes computational biology, bioinformatics analysis and understanding genetic interactions and how they affect the cellular functions. This experience and immense knowledge inform his mindful and robust approach to founding Gene Solutions. Hoa’s experience spans the globe having lived, studied and worked in Vietnam and USA.In this episode, Hoa shares his journey of how he moved to the USA to pursue an advanced degree in computational biology. Starting from having an interest in biotech, he also shares how he was able to work with Professor Jun Hyong Kim at the University of Pennsylvania and broaden his expertise to bioinformatics. This knowledge helped him to develop new methods of combining wet lab protocol and dry lab analysis for next generation sequencing (NGS). He goes on to mention that he is very passionate about making new technology available to all and thus brought these new novel methods of NGS back to Vietnam in the form of Gene Solutions. In this episode, Hoa also shares about the groundbreaking work being done at Gene Solutions, including their way of staying ahead of competition while aiming to keep solutions affordable and accessible to the masses. He also briefly talks about Gene Solution’s technology, focusing on their two main pillars of reproductive health and clinical oncology, and how it varies from older tests and their strategies of expansion into various new geographical markets. Lastly, he describes the typical challenges that a company would face when they are first starting up and the importance of good teamwork.Host: Aakash S/O Naresh Kumar Editors: Hana Maldivita Tambrin, Aakash S/O Naresh Kumar, Dillon Chew, John Joson Ng01:30 Hoa's Background and Early Career03:58 Founding of Gene Solutions07:05 Gaps that Gene Solutions Aims to Solve12:03 Differences Between Gene Solutions’ New Methods and Old Methods20:17 Challenges Faced by Gene Solutions in Expansion to New Markets26:32 Importance of Partnerships37:03 Advice for Aspiring Scientists and Entrepreneurs

Dr. Ivan Horak is currently the CEO and founder of Tikva Allocell, a biotech company whose mission is to develop safe, effective, readily available and affordable “off-the-shelf” T cell therapies by leveraging excellent safety profile of proprietary technologies that enhance the T cell's performance to treat cancer.In this episode, Ivan shares his journey from having an interest in becoming a medical oncologist. He also shares how his experience in working in some of the top oncology institutes in Central Europe to working in the United States helped shape his early career before moving into Singapore, where he worked with Tessa and finally set out to develop Tikva Allocell. Tikva Allocell is focused on creating therapy using proprietary IP protected platform to drive the next breakthrough in cancer therapy. In this episode, Ivan also shares about the groundbreaking work being done at Tikva, and also the typical challenges that a company would face when they are first starting up. He goes on to talk about making therapies affordable, how to manage scaling up and also the importance of collaboration. He also mentions the intricacies of VCs and also how they function.Host: John Joson Ng Editors: Hana Maldivita Tambrin, Aakash S/O Naresh Kumar, Dillon Chew, John Joson Ng01:37 Ivan's Background and Early Career 04:46 Founding of Tikva 11:41 Importance of Collaborations 14:26 Tikva's recent milestones 15:36 VC mindset20:20 Advice for Aspiring Bioentrepreneurs and Final Thoughts

Dr. Joshua Wang is currently the CEO and founder of VerImmune, a biotech company focused on developing novel virus inspired particle technology platform that can be used as a delivery system to target cancers.In this episode, Josh shares his journey from having an interest in infectious diseases to leading a biotech startup that spans across the US and Singapore. VerImmune specializes in developing Virus-Inspired Particle (VIP) technology for targeting cancers. Josh discusses his academic background, including his PhD work at Johns Hopkins, and how serendipitous events led him from vaccine research to entrepreneurship. He explains the mechanics and advantages of VerImmune's VIP technology, its application in cancer treatment, and its potential for other therapeutic areas. The episode also covers challenges in biotech entrepreneurship, the importance of manufacturing and scalability, and the strategic decisions behind relocating some operations to Singapore. Dr. Wang offers valuable advice for aspiring biotech founders, emphasizing the significance of discernment, persistence, and leveraging global opportunities.Host: Dillon ChewEditors: Hana Maldivita Tambrin, Aakash S/O Naresh Kumar, Dillon Chew, John Joson Ng00:00 Josh's Background and Early Career 05:13 Founding his first Startup 06:27 Challenges in the Vaccine Business 07:46 VerImmune and their VIP Technology 21:24 Collaborations and Global Expansion 29:48 Advice for Aspiring Bioentrepreneurs 32:38 Conclusion and Final Thoughts

Ritika Khetawat is the founder of MissionBridge, a fundraising advisory firm that empowers Singapore’s biotech and medtech ventures to secure the capital they need. In this episode, Ritika discusses her transition from investment banking at Goldman Sachs and Morgan Stanley to supporting healthcare startups through MissionBridge. She shares her insights into the unique challenges of biotech fundraising, emphasizing the need for strategic planning, strong storytelling, and relationship-building with investors. Ritika explains MissionBridge’s mission to “democratize fundraising” by simplifying the process for founders and bridging the gap between early-stage innovation and global funding opportunities. She also highlights the importance of optionality in biotech pipelines and adapting to market dynamics during the “biotech winter.”Host: Dillon ChewEditors: Hana Maldivita Tambrin, Aakash S/O Naresh Kumar, Dillon Chew, John Joson Ng01:17 Introduction 09:22 Various Sources of Funding for Startups22:19 Common Challenges and Mistakes Made During Fundraising30:00 Selecting a Good VC Partner36:47 Future of MissionBridge and Emerging Trends in Singapore

Dr David M. Epstein is the co-founder and president of PairX Bio, a company that specializes in the next generation of cancer selective biologics.In this episode, David shares his experience and journey from working in various biotech companies and big pharma institutions to eventually building his own companies. One of these is Pairx Bio, a company specializing in the next generation of cancer biologics. David stresses the importance of how being able to follow the science and being transparent and open with the discussions on data collected from research projects plays a key role in the success of a company. He also touches on the success of targeted cancer therapies, some of which has led to an increase in lifespan, as well as the limitations in terms of the range of diseases that can be treated with this therapy. He also highlights the future of therapeutics in general, discussing the push in biotherapeutics and immunotherapeutics and expanding the horizon where these new innovative treatments can be effective. Lastly, he touches on the importance of how to handle IP matters and protecting one’s IP.Host: Aakash S/O Naresh KumarEditors: Hana Maldivita Tambrin, Dillon Chew, Jessie Wong, John Joson NgThe show notes and transcripts for the episode can be found on nucleatesingapore.substack.com. For feedback or recommendations on who we should talk to next, please reach out to the team via singapore@nucleate.org.01:01 Introduction05:10 Origins of Pairx Bio and Key Characteristics For a Successful Startup13:18 Key differences in the process of IP patenting18:22 Singapore VS USA Biotech Ecosystems20:51 Future of Singapore’s Biotech Ecosystem

Dr. Alessandro Falcone is the Head of JLABS Singapore. In this episode, Alessandro talks about his transition from clinical medicine to business consulting, eventually landing in leadership roles at major pharmaceutical companies. He explains the mission of JLABS Singapore, a collaboration between Johnson & Johnson and Singapore’s Economic Development Board, which aims to nurture early-stage biotech and medtech startups. Alessandro highlights JLABS’ shift from a traditional lab incubator to a Universal model, which emphasizes advisory support, mentorship, and global networking opportunities for resident startups. He also discusses Singapore’s biotech ecosystem and shares his insights on building resilient companies amid the "biotech winter" funding challenges.Host: John Joson NgEditors: Hana Maldivita Tambrin, Aakash S/O Naresh Kumar, Dillon Chew, Jessie Wong, John Joson NgThe show notes and transcripts for the episode can be found on nucleatesingapore.substack.com. For feedback or recommendations on who we should talk to next, please reach out to the team via singapore@nucleate.org.01:23 Introduction05:37 JLABS Singapore: Mission and Role16:38 Challenges and Successes18:46 Singapore’s Ecosystem31:09 Navigating Career Transitions

Loong Wang is the CEO and Co-Founder of QDX, a company specializing in computational drug discovery using quantum mechanics and supercomputing. In this episode, Loong discusses his journey from supercomputing at the Australian National University to founding multiple startups in distributed computing and blockchain—before making a significant pivot to biotechnology. His deep dive into quantum chemistry aims to address complex drug discovery challenges by simulating atomic and molecular behaviors at a fundamental level. He also touches on the potential for quantum chemistry to revolutionize high-throughput screening methods that big pharmaceutical companies currently rely on, making these processes faster, cheaper, and more precise. He emphasizes understanding the nuances of biomedical problems and the need for a multidisciplinary approach in developing groundbreaking solutions.Host: John Joson NgEditors: Jessie Wong, John Joson NgThe show notes and transcripts for the episode can be found on nucleatesingapore.substack.com. For feedback or recommendations on who we should talk to next, please reach out to Joson Ng via johnjoson.n@nucleate.org.01:02 Introduction06:16 Understanding Quantum Mechanics in Drug Discovery18:53 Challenges in Biotech: Collaboration and Simulations26:30 Entrepreneurship, IP Strategy, and Scaling Up42:22 Advice for Non-Traditional Entrants to Biotech

Fengru Lin is the Founder and CEO of TurtleTree, a pioneering biotechnology company that has successfully developed the world’s first sustainably produced lactoferrin “LF+” using precision fermentation technology.In this episode, Fengru Lin shares her journey from a tech career at Google and Salesforce to leading biotech innovations at TurtleTree. Inspired by challenges in replicating traditional cheese-making in Asia, she envisioned revolutionizing the dairy industry. Fengru discusses TurtleTree’s shift from cell-based milk to producing high-value proteins like lactoferrin, used in infant nutrition and supplements. She emphasizes the importance of market-driven innovation, sustainable ingredients, and the role of a mission-focused team in staying competitive in the dynamic biotech space.Host: Jessie WongEditors: Jessie Wong, John Joson Ng The show notes and transcripts for the episode can be found on nucleatesingapore.substack.com. For feedback or recommendations on who we should talk to next, please reach out to Joson Ng via johnjoson.n@nucleate.org.01:00 Introduction05:51 Pivoting from Cell-Based Milk to Lactoferrin Production16:02 Challenges and Strategies in Building TurtleTree20:14 Consumer Perception and Adoption of Precision Fermentation Products26:09 TurtleTree’s Role in Singapore’s 2030 Sustainable Food Initiative30:58 Balancing Sciences and Business in Biotech Startups

Dr. Lisa Ooi is the Senior Vice President of Strategy at Hummingbird Bioscience, a leading biotech company in Singapore focused on antibody therapeutics. In this episode, Dr. Ooi discusses her journey from her PhD at Stanford to her current role, highlighting her experience in biomedical research and corporate strategy. She delves into Hummingbird Bioscience's innovative platform for developing antibody-based therapies, sharing insights on the company's strategic direction, the challenges of drug development, and the potential impact of their work on cancer treatment and beyond. Dr. Ooi also explores the reasons behind Hummingbird Bioscience's success in attracting investment and the unique advantages of being based in Singapore.Host: Jessie WongEditors: Jessie Wong, John Joson Ng The show notes and transcripts for the episode can be found on nucleatesingapore.substack.com. For feedback or recommendations on who we should talk to next, please reach out to Joson Ng via johnjoson.n@nucleate.org. 01:00 Introduction10:06 Establishing Hummingbird Bioscience in Singapore14:22 Innovative Antibody and ADC Development Strategy23:37 Revolutionizing Cancer Treatment with Dual Payload ADCs28:56 Hummingbird Bioscience's Role in Singapore's Biotech Ecosystem

Dr. Adam Gregory is a Partner and Patent Attorney at Mewburn Ellis LLP. He works with biotech companies to build and manage their patent portfolios, drafting patent applications and co-ordinating prosecution worldwide. In this episode, he highlights success stories from Singapore’s vibrant biotech scene, including Enleofen Bio and Hummingbird Bioscience, and discusses the evolving nature of patent strategies in the face of emerging technologies like AI and gene editing. From understanding the differences between patents, trademarks, and copyrights to exploring the patent application process and common pitfalls, this episode is packed with valuable information for anyone in the biotech industry.Host: John Joson NgEditors: Jessie Wong, John Joson NgThe show notes and transcripts for the episode can be found on nucleatesingapore.substack.com. For feedback or recommendations on who we should talk to next, please reach out to Joson Ng via johnjoson.n@nucleate.org.01:02 Introduction08:50 The patent application process14:57 Strategic IP management and common pitfalls27:06 Success stories from Singapore biotech36:18 Emerging technologies and future trends

Dr. Robert Ang is the CEO of Vor Bio, a clinical-stage cell and genome engineering therapy company. In this episode, Dr. Ang discusses the challenges of treating cancer, particularly acute myeloid leukemia (AML), and the need for new and innovative approaches. The conversation delves into the challenges of navigating clinical trials during the pandemic and securing funding for research and development. Lastly, he explains how Vor Bio is using cell and gene therapies, such as CAR-T cells and genome engineering, to target AML and potentially cure patients. Host: John Joson NgEditors: Jessie Wong, John Joson NgThe show notes and transcripts for the episode can be found onnucleatesingapore.substack.com. For feedback or recommendations on who we should talk to next, please reach out to Joson Ng via johnjoson.n@nucleate.org.01:15 Introduction07:47 Cancer and treatment modalities12:02 Vor’s approach to treating AML31:55 Investing in clinical manufacturing34:21 Navigating clinical trials and funding during the pandemic39:53 Looking ahead

Dr. Guy Heathers is the Chief Business Officer and one of the co-founders of Albatroz Therapeutics. In this episode, Dr. Guy Heathers shares his insights and experiences in the biotech industry, focusing on the challenges and opportunities faced by startups in Singapore. He discusses the importance of patent protection, the need for strong product development capabilities, and the significance of effective interaction with pharma companies. Dr. Heathers emphasizes the value of pursuing first-in-class innovations and the importance of confidence and conviction in the entrepreneurial journey. He also provides advice for academic trainees and early career professionals, encouraging them to take their time and enjoy the process of building a successful career in biotech.Host: John Joson NgEditors: Jessie Wong, John Joson NgThe show notes and transcripts for the episode can be found on nucleatesingapore.substack.com. For feedback or recommendations on who we should talk to next, please reach out to Joson Ng via johnjoson.n@nucleate.org.01:22 Establishing Albatroz Therapeutics06:59 Challenges and deliverables in biotech startups10:11 Differences in modalities and investor appetite16:28 Key ingredients for competitive biotech startups25:29 Personal advice and future outlook

Dr. Guy Heathers is the Chief Business Officer and one of the co-founders of Albatroz Therapeutics, a preclinical stage biotech company focused on developing therapeutic antibodies and antibody drug conjugates for the treatment of solid tumors and arthritis. In this episode, Dr. Guy Heathers shares his extensive experience in the biotech industry and discusses the challenges and opportunities in Singapore's biotech ecosystem. He talks about how he became involved in building the biotech industry in Singapore. Dr. Heathers also reflects on the progress and setbacks in the Singapore biotech scene, highlighting the importance of having a clear business strategy and the need for specialized biotech investors. He emphasizes the global mindset and the potential for biotech companies to make a significant impact on a global scale.Host: John Joson NgEditors: Jessie Wong, John Joson NgThe show notes and transcripts for the episode can be found onnucleatesingapore.substack.com. For feedback or recommendations on who we should talk to next, please reach out to Joson Ng via johnjoson.n@nucleate.org.01:03 Introduction06:28 Getting invovled with Singapore's nascent biotech ecosystem10:17 Early successes16:16 Mindset shift26:37 Tessa's closure and lessons learned

Levana Sani is the co-founder and CEO of NalaGenetics. In this episode, Levana shares how her background in biochemistry and her MBA from Harvard Business School helped shape her understanding of the business side of science. She explains the four main problems NalaGenetics aims to solve in the field of genetic testing and the challenges they faced in the early stages. Additionally, she highlights the differences in commercialisation in Singapore and Indonesia, and the current challenges faced with the adoption and application of pharmacogenomics in clinics.Host: Jessie WongEditors: Jessie Wong, John Joson NgThe show notes and transcripts for the episode can be found onnucleatesingapore.substack.com. For feedback or recommendations on who we should talk to next, please reach out to Joson Ng via johnjoson.n@nucleate.org.01:00 Introduction05:09 Early beginnings of NalaGenetics12:11 Product development and market expansion17:10 Technology and democratization of genetics24:15 Future outlook

Dr. Massimo Alberti is the CEO and co-founder of REVIVO BioSystems. In this episode, Dr. Alberti shares valuable insights into the process of spinning off a technology from an academic setting. He discusses the genesis of REVIVO BioSystems, the development of their innovative 4D human tissue models, and the pivotal role of perseverance, interdisciplinary collaboration, and client feedback in shaping REVIVO BioSystems' trajectory. Aspiring biomedical entrepreneurs and young scientists will find inspiration in Dr. Alberti's entrepreneurial journey, along with actionable advice for navigating the transition from academia to startup.Host: Jessie WongEditors: Jessie Wong, John Joson NgThe show notes and transcripts for the episode can be found onnucleatesingapore.substack.com. For feedback or recommendations on who we should talk to next, please reach out to Joson Ng via johnjoson.n@nucleate.org.01:07 Introduction04:52 What REVIVO BioSystems offers09:13 Challenges and triumphs of early development11:08 Navigating the investment landscape24:02 Overcoming regulatory hurdles and industry standards32:51 Advice for aspiring entrepreneurs

Dr. Carolyn Ng is the Managing Director and Partner of TPG Life Sciences Innovations. With a decade of expertise in life sciences investment under her belt, she's the powerhouse behind infusing capital into groundbreaking startup companies in precision oncology, immunology, ophthalmology, metabolic diseases, and rare diseases. In this episode, Dr. Carolyn Ng shares her journey from academia to venture capital and discusses the investment thesis of her company. She also shares her insights on startup success factors - robust IP, strategic partnerships, and a stellar team. Plus, get the lowdown on navigating macroeconomic headwinds and savvy exit strategies for biotech companies.Host: John Joson NgEditors: Jessie Wong, John Joson NgThe show notes and transcripts for the episode can be found on nucleatesingapore.substack.com. For feedback or recommendations on who we should talk to next, please reach out to Joson Ng via johnjoson.n@nucleate.org. 00:58 Introduction 03:50 Journey to venture capital 09:34 Assessing biotech startups and their risk profiles 19:56 Keeping up with biotech 27:47 Different flavors of biotech 29:59 Advice for entrepreneurs

Dr. Jonathan Ng is the CEO and founder of Iterative Health, a company that focuses on AI diagnostics for gastrointestinal diseases. In this episode, Dr. Jonathan Ng discusses his journey from medical school to entrepreneurship and the development of AI diagnostics for gastrointestinal diseases. He shares his experiences in healthcare and the challenges he faced in starting a company focused on AI. He also talks about the importance of mentorship and the role of AI in transforming healthcare. He emphasizes the need for business model innovation and the gradual adoption of AI tools in order to ensure patient safety and improve outcomes.Host: John Joson NgEditors: Jessie Wong, John Joson NgThe show notes and transcripts for the episode can be found on ⁠nucleatesingapore.substack.com⁠. For feedback or recommendations on who we should talk to next, please reach out to Joson Ng via ⁠johnjoson.n@nucleate.xyz⁠. 01:22 Introduction04:04 The inception of Iterative Health06:40 Challenges and evolution of AI adoption09:42 Entrepreneurial journey and mentorship11:29 Comparison of ecosystems13:16 Future of AI in healthcare19:15 Advice for entrepreneurs

Prof. Dean Ho is the Provost’s Chair Professor and Head of the Department of Biomedical Engineering at the National University of Singapore. He is also the Director of the Institute for Digital Medicine (WisDM) and The N.1 Institute for Health, and one of the Scientific Co-Founders of KYAN Technologies. In this episode, Prof. Ho discusses the importance of accessibility and community in fostering innovation. He highlights the role of academia in bridging the gap between innovation and real-world impact. Prof. Ho also shares his experience in setting up a biotech company in both the US and Singapore, emphasizing the ease and agility of the Singaporean ecosystem. He discusses the opportunities for AI in healthcare, particularly in clinical trial design and digital therapeutics. Prof. Ho also mentions the importance of a human talent pipeline to support the growing biotech industry in Singapore.Host: John Joson NgEditors: Jessie Wong, John Joson NgThe show notes and transcripts for the episode can be found on nucleatesingapore.substack.com. For feedback or recommendations on who we should talk to next, please reach out to Joson Ng via johnjoson.n@nucleate.xyz. 01:27 Introduction 06:32 The importance of impact 09:53 Singapore’s advantages as an ecosystem 21:36 CURATE.AI, Optim.AI, and other AI technologies 29:39 Digital therapeutics (DTx) 35:56 Growing the local talent pipeline for the biotech industry 42:55 Resources for those interested in biotech